 |
|
Move your mouse over the questions on the left hand side to view the answers. |
 |
|
What kind of Company is Santaris Pharma?
|
|
Santaris Pharma is a biopharmaceutical company developing novel drug candidates for targeted RNA-therapy based on its proprietary LNA chemistry.
|
|
Is Santaris Pharma represented outside Denmark?
|
|
Yes, Santaris Pharma has subsidiary in San Diego California, USA
|
|
What is the financial situation of Santaris Pharma
|
|
The Company is well financed through 2010.
|
|
Who are Santaris Pharma's pharmaceutical partners?
|
|
Enzon Pharmaceuticals, GlaxoSmithKline and Wyeth Pharmaceuticals.
|
|
What is RNA?
|
|
RNA (ribonucleic acid) is a long linear polymer of nucleotides found primarily in the cytoplasm of a cell where it is associated with microsomes; it transmits genetic information from DNA to the cytoplasm and controls certain chemical processes in the cell)
|
|
What is antisense?
|
|
Antisense is a molecule which interacts with a complementary strand of nucleic acids (RNA) to suppress its transcription.
|
|
What makes Santaris Pharma different?
|
|
Santaris Pharma holds all international therapeutic rights to the basic LNA chemistry. LNA is the chemistry of choice for RNA-targeting therapeutics.
|
|
Why is RNA a good target for therapeutics?
|
|
There is a linkage between genes and diseases, and RNA-targeting is the most direct way to translate this genomic information into drugs. LNA chemistry is the chemistry-of-choice for RNA-targeting therapeutics.
|
|
What is microRNA?
|
microRNAs are a relatively newly discovered class of short RNAs that function naturally in cells to fine-tune the expression of genes.
As a novel class of targets they have created significant excitement in the scientific community and drug industry where they are increasingly considered promising therapeutic intervention points.
|
|
Who are the owners of Santaris Pharma?
|
|
A group of international investors own Santaris Pharma. The group comprises Forbion Capital Partners, Bankinvest, Innovations Capital, Sunstone Capital, Seventure, Global lifescience ventures, LD, Novo, Teknoinvest and Gilde Healthcare Partners.
|
|
Who is the Chairman of the Board of the company?
|
|
Flemming Ørnskov, President, Pharmaceuticals and OTC, Bausch & Lomb, Inc.
|
|
Who is the CEO of the Company?
|
|
Søren Tulstrup is the CEO of Santaris Pharma.
|
|
What are the Company's core competences?
|
|
Santaris Pharma's unique and proprietary LNA Drug Platform and an exceptionally effective and efficient Drug Discovery Engine.
|
|
What kind of technology is LNA?
|
|
LNA, Locked Nucleic Acid, technology is an antisense technology which is used to develop novel RNA-targeted therapeutics. LNA molecules are built into synthetic DNA oligonucleotides that have the ability to specifically bind to complementary sequences of messengerRNAs and microRNAs.
|
|
How do LNA-based RNA drugs differ from other approaches?
|
|
LNA-based drugs are characterised by a number of unique properties, among which are high biostability and an unprecedented target affinity, which enable strong pharmacological activity to be packed into metabolically stable, shorter than usual oligonucleotides.
|
|
How do LNA-based drugs differ from siRNA drug candidates?
|
|
LNA oligonucleotides are short, single stranded and can be delivered into the cells without additives. siRNA drugs are longer, double stranded and face delivery problems.
|
|
Where is Santaris Pharma situated?
|
|
The Company is headquartered in the science park SCION DTU in Hørsholm close to Copenhagen, Denmark's capital.
|
|
When was the company founded?
|
|
Santaris Pharma was founded in 2003 through a merger between two Danish biotecnology companies.
|
|
 |